Study S001082

A Randomised Trial Investigating Steady State Semaglutide Exposure of 25 and 50 mg of Oral Semaglutide in Different Formulations in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04524832
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 290
Start: 2020-09-29
Primary completion: 2022-02-25
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Oral semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1242-2643; REGISTRY:2019-004157-80; NIH:2019

Registered primary outcomes

Area under the semaglutide plasma concentration - time curve during a dosing interval at steady state (AUC0-24h,sema,SS) [From 0 to 24 hours after the last dosing of oral semaglutide 25 mg on visit 8, day 84]
Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS) [From 0 to 24 hours after the last dosing of oral semaglutide 50 mg on visit 10, day 112]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.